

Clinical trials of epoetin alfa

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
epoetin alfa vs placebo			
HEBE III , 2010 n=263/266 follow-up: 6 weeks	single bolus of 60,000 IU epoetin alfa administered intravenously within three hours after a successful PCI versus control	patients with a first ST-elevation MI and a successful PCI	Parallel groups open the Netherlands

More details and results :

- increasing hemoglobin concentration for acute myocardial infarction in patients undergoing PCI at <http://www.trialresultscenter.org/go-Q470>

References

HEBE III, 2010:

Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010 Nov;31:2593-600 [20802250] [10.1093/eurheartj/ehq304](https://doi.org/10.1093/eurheartj/ehq304)

2 heart failure

Trial	Treatments	Patients	Trials design and methods
darbepoetin alfa vs placebo			
STAMINA-HeFT (Ghali) , 2008 [NCT00049985] n=162/157 follow-up: 27 weeks	darbepoetin alfa SC every 2 weeks for 1 year (target hemoglobin, 14.0+/-1.0 g/dL). versus placebo	Patients with symptomatic HF, left ventricular ejection fraction $\leq 40\%$, and hemoglobin ≥ 9.0 g/dL and ≤ 12.5 g/dL	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
van Veldhuisen , 2007 [NCT00086086] n=110/55 follow-up: 27 weeks	darbepoetin alfa subcutaneously every 2 weeks for 26 weeks at a starting weight-adjusted dose of 0.75 mcg/kg or a fixed dose of 50 mcg versus placebo	Patients with chronic heart failure (≥ 3 months), left ventricular ejection fraction $\leq 40\%$, and Hb 9.0 to 12.5 g/dL	Parallel groups double blind
Ponikowski , 2007 [NCT00117234] n=19/22 follow-up: 27 weeks	Subcutaneous (SC) Darbepoetin Alfa versus subcutaneous placebo	patients with Symptomatic Congestive Heart Failure (CHF) and Anemia	Parallel groups double blind
Parissis , 2008 n=21/11 follow-up:	3-month darbepoetin alpha regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron	CHF patients NYHA II-III, LV ejection fraction [EF] $< 40\%$, hemoglobin level < 12.5 g/dL, serum creatinine level < 2.5 mg/dL	
Parissis , 2009 n=30 follow-up:	3-month darbepoetin alfa regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron	patients with CHF (LV ejection fraction [LVEF] $< 40\%$, hemoglobin < 12.5 g/dl, and serum creatinine < 2.5 mg/dl	
Kourea , 2008 n=21/20 follow-up:	3-month darbepoietin-alpha at 1.5 microg/Kg every 20 days plus iron orally versus placebo plus iron orally	CHF patients NYHA II-III; left ventricular ejection fraction $< 40\%$; hemoglobin < 12.5 g/dl; serum creatinine < 2.5 mg/dl	double blind

More details and results :

- increasing hemoglobin concentration for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q301>

References

STAMINA-HeFT (Ghali), 2008:

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. *Circulation* 2008;117:526-35 [18195176]

van Veldhuisen, 2007:

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. *Eur Heart J* 2007;28:2208-16 [17681958]

Ponikowski, 2007:

Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol* 2007;49:753-62 [17306703]

Parissis, 2008:

Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaïdis I, Ikonomidis I, Filippatos G, Kremastinos DT Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008;155:751.e1-7 [18371487]

Parissis, 2009:

Parissis JT, Kourea K, Andreadou I, Ikonomidis I, Markantonis S, Ioannidis K, Paraskevaïdis I, Iliodromitis E, Filippatos G, Kremastinos DT Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009;103:1134-8 [19361602]

Kourea, 2008:

Kourea K, Parissis JT, Farmakis D, Paraskevaïdis I, Panou F, Filippatos G, Kremastinos DT Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008;15:365-9 [18525396]

Entry terms: taspoglutide, taspoglutide,